The safety profile shown in Tables 1, 2 suggested that the most common AEs were gastrointestinal AEs (diarrhea, nausea, vomiting, anorexia, and oxaliplatin-related abdominal pain), hematologic AEs (thrombocytopenia, neutropenia, leukopenia and anemia), rash, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) elevated, hand-foot skin reaction, fever, hypertension and hypothyroidism in combined therapy. The gene discussed is GPT; the disease is neutropenia.